Risvutatug rezetecan clinical trials
Also written HS-20093 and GSK5764227.
ClinicalTrials.gov finds 11 studies for risvutatug rezetecan. How that becomes 32 here
Every study that search finds has been read, to see whether and how it gives risvutatug rezetecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 11Found by its intervention search · See all 11 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 9 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +24Give it under a name that search misses: a biosimilar’s code or a misspelling
- 35Give risvutatug rezetecan to participants
- −3Give it beside what is tested
- 32Test it: the count on this site
Get an email when these change. Save the risvutatug rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2026 (11)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 9 |
| 2025 | 8 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 2
Hansoh BioMedical R&D Company (19) · GlaxoSmithKline (8) · Shanghai Hansoh Biomedical Co., Ltd (2) · University Health Network, Toronto (1) · Nader Sanai (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Adebrelimab (2) · Remzistotug (1) · Belrestotug (1) · Nelistotug (1) · Alveltamig (1) · Granulocyte Colony-Stimulating Factor (1) · Ivonescimab (1) · Zeprumetostat (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 5 most studied
New when their studies opened, with risvutatug rezetecan beside them; studies of each.
- 1Nimotuzumab
- 1PARP1 Inhibitor HS-10502
- 1Apatinib
- 1Mocertatug rezetecan
- 1Platinum Compounds
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test risvutatug rezetecan, phase 3 first.
- Nov 2027A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]Phase 3 · GlaxoSmithKline
- Nov 2027A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerPhase 3 · Hansoh BioMedical R&D Company
- Dec 2026ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Phase 1 · Hansoh BioMedical R&D Company
- Dec 2026HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction AdenocarcinomaPhase 1 · Hansoh BioMedical R&D Company
- Jul 2027A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain MetastasesEarly Phase 1 · Nader Sanai
- Nov 2027A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)Phase 1/2 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses risvutatug rezetecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 32
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]RecruitingPhase 3GlaxoSmithKlineNCT07099898Against topotecan in relapsed small cell lung cancerWritten as Risvutatug rezetecan (Ris-Rez)Report a problem
- A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung CancerNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07899086With ivonescimab, with or without chemotherapy, in lung cancerWritten as HS-20093Report a problem
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07892625With ZG006, with or without adebrelimab, in small cell lung cancerWritten as HS-20093 for InjectionReport a problem
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT07824882With adebrelimab, against it alone, in non-squamous lung cancerWritten as HS-20093 for InjectionReport a problem
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)RecruitingPhase 1/2GlaxoSmithKlineNCT06885034Alone at several doses in colorectal and pancreatic cancerWritten as Risvutatug RezetecanReport a problem
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingPhase 3GlaxoSmithKlineNCT07802704Against standard care in castration-resistant prostate cancerWritten as Risvutatug rezetecan (Ris-Rez)Report a problem
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 2University Health Network, TorontoNCT07408063Alone or with dostarlimab in head and neck cancer, for biomarkersWritten as GSK5764227Report a problem
- A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)RecruitingPhase 1/2GlaxoSmithKlineNCT07602777Alone in sarcomas, with or without G-CSFWritten as Ris-RezReport a problem
- A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsRecruitingPhase 1GlaxoSmithKlineNCT07277270With standard treatments in colorectal and prostate cancerWritten as GSK5764227Report a problem
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingPhase 1/2GlaxoSmithKlineNCT07602855With ivonescimab in solid tumoursWritten as Risvutatug rezetecanReport a problem
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07621601Against chemotherapy in pretreated oesophageal squamous cancerWritten as HS-20093 for InjectionReport a problem
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Alone or with chemotherapy, checkpoint inhibitors or tarlatamabWritten as Ris-RezReport a problem
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07464327With adebrelimab, against docetaxel, in non-squamous lung cancerWritten as HS-20093Report a problem
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain MetastasesRecruitingEarly Phase 1Nader SanaiNCT07268053Before and after surgery in recurrent glioma and brain metastasesWritten as Risvutatug rezetecanReport a problem
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106With rezvilutamide and abiraterone in one prostate cancer cohortWritten as HS-20093 for InjectionReport a problem
- Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07186452Its levels with and without itraconazoleWritten as HS-20093Report a problem
- Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07115446With HRS-5041 in advanced prostate cancerWritten as HS-20093Report a problem
- Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung CancerNot yet recruitingPhase 1Shanghai Hansoh Biomedical Co., LtdNCT07063407With adebrelimab in extensive-stage small cell lung cancerWritten as HS-20093 in combination with AdebrelimabReport a problem
- ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06825624With bevacizumab and chemotherapy in colorectal cancerWritten as HS-20093Report a problem
- HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06112704Alone in oesophageal cancerWritten as HS-20093Report a problem
See all 32 studies that test risvutatug rezetecan →
Tested on its own · 16 — no other medicine in its arm
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]RecruitingPhase 3GlaxoSmithKlineNCT07099898Against topotecan in relapsed small cell lung cancerWritten as Risvutatug rezetecan (Ris-Rez)Report a problem
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)RecruitingPhase 1/2GlaxoSmithKlineNCT06885034Alone at several doses in colorectal and pancreatic cancerWritten as Risvutatug RezetecanReport a problem
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingPhase 3GlaxoSmithKlineNCT07802704Against standard care in castration-resistant prostate cancerWritten as Risvutatug rezetecan (Ris-Rez)Report a problem
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07621601Against chemotherapy in pretreated oesophageal squamous cancerWritten as HS-20093 for InjectionReport a problem
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT07464327With adebrelimab, against docetaxel, in non-squamous lung cancerWritten as HS-20093Report a problem
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain MetastasesRecruitingEarly Phase 1Nader SanaiNCT07268053Before and after surgery in recurrent glioma and brain metastasesWritten as Risvutatug rezetecanReport a problem
- HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06112704Alone in oesophageal cancerWritten as HS-20093Report a problem
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT05830123Alone in osteosarcoma and other sarcomasWritten as HS-20093Report a problem
- ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06007729Alone in head and neck cancerWritten as HS-20093Report a problem
- ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid TumorsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT06001255Alone in castration-resistant prostate cancerWritten as HS-20093Report a problem
- A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerNot yet recruitingPhase 3Hansoh BioMedical R&D CompanyNCT06526624Against surveillance after chemoradiotherapy, limited-stage small cell lung cancerWritten as HS-20093Report a problem
- HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction AdenocarcinomaActive, not recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07462923Alone in gastric and gastro-oesophageal junction cancerWritten as HS-20093 for injectionReport a problem
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedPhase 3Hansoh BioMedical R&D CompanyNCT06935409Against gemcitabine with docetaxel in osteosarcomaWritten as HS-20093Report a problem
- ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerCompletedPhase 3Hansoh BioMedical R&D CompanyNCT06498479Against topotecan in relapsed small cell lung cancerWritten as HS-20093Report a problem
- ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung CancerWithdrawnPhase 2Hansoh BioMedical R&D CompanyNCT06052423Alone in extensive-stage small cell lung cancerWritten as HS-20093Report a problem
- ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid TumorsStatus unknownPhase 1Shanghai Hansoh Biomedical Co., LtdNCT05276609Alone in solid tumours, first in peopleWritten as HS-20093 (Phase Ia: Dose escalation)Report a problem
Tested with established drugs · 8 — they are given beside it
- A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung CancerNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07899086With ivonescimab, with or without chemotherapy, in lung cancerWritten as HS-20093Report a problem
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 2University Health Network, TorontoNCT07408063Alone or with dostarlimab in head and neck cancer, for biomarkersWritten as GSK5764227Report a problem
- A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsRecruitingPhase 1GlaxoSmithKlineNCT07277270With standard treatments in colorectal and prostate cancerWritten as GSK5764227Report a problem
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Alone or with chemotherapy, checkpoint inhibitors or tarlatamabWritten as Ris-RezReport a problem
- Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07186452Its levels with and without itraconazoleWritten as HS-20093Report a problem
- ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06825624With bevacizumab and chemotherapy in colorectal cancerWritten as HS-20093Report a problem
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT06699576With anlotinib, epirubicin or adebrelimab in sarcomaWritten as HS-20093Report a problem
- ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06332170With adebrelimab, cetuximab, chemotherapy or enzalutamideWritten as HS-20093Report a problem
Tested in a combination · 8 — another drug in the study is under test too
- A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT07892625With ZG006, with or without adebrelimab, in small cell lung cancerWritten as HS-20093 for InjectionReport a problem
- A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 2Hansoh BioMedical R&D CompanyNCT07824882With adebrelimab, against it alone, in non-squamous lung cancerWritten as HS-20093 for InjectionReport a problem
- A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)RecruitingPhase 1/2GlaxoSmithKlineNCT07602777Alone in sarcomas, with or without G-CSFWritten as Ris-RezReport a problem
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingPhase 1/2GlaxoSmithKlineNCT07602855With ivonescimab in solid tumoursWritten as Risvutatug rezetecanReport a problem
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106With rezvilutamide and abiraterone in one prostate cancer cohortWritten as HS-20093 for InjectionReport a problem
- Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07115446With HRS-5041 in advanced prostate cancerWritten as HS-20093Report a problem
- Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung CancerNot yet recruitingPhase 1Shanghai Hansoh Biomedical Co., LtdNCT07063407With adebrelimab in extensive-stage small cell lung cancerWritten as HS-20093 in combination with AdebrelimabReport a problem
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT05277051With dostarlimab in one arm of a first-in-people studyWritten as GSK5764227Report a problem
Beside a new treatment under test · 3 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with risvutatug rezetecan: nimotuzumab 1 · PARP1 Inhibitor HS-10502 1 · apatinib 1 · mocertatug rezetecan 1 · Platinum Compounds 1
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingPhase 1/2Zhejiang UniversityNCT07736612Given with HRS-2329 in some pancreatic cancer armsWritten as HS-20093Report a problem
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06769425Given with HS-10502, the drug being dosed, in one cohortWritten as HS-10502 + HS-20093Report a problem
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06963502Given with HS-10370 in some armsWritten as HS-20093Report a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered2
Codes
What other systems call risvutatug rezetecan · ClinicalTrials.gg INT015531
- UNII (FDA) 7T9A6CKG67RISVUTATUG REZETECANOne source FDA
- NCI Thesaurus C187121Risvutatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7T9A6CKG67 | RISVUTATUG REZETECAN | One source FDA |
| NCI Thesaurus | C187121 | Risvutatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.